Blood markers may predict ibrutinib success in tough leukemia

NCT ID NCT02827617

Completed Knowledge-focused Sponsor: Oncology Institute of Southern Switzerland Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study followed 56 people with a high-risk form of chronic lymphocytic leukemia (CLL) who were taking the drug ibrutinib. Researchers looked for changes in the blood that could show early on whether the drug was working or failing. The goal is to find simple markers that help doctors make better treatment decisions for this hard-to-treat cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Ibrutinib
What this could lead to: If successful, this could help doctors identify early which patients benefit from ibrutinib and which might need a different treatment.
What could go wrong: This is a small, observational study that does not test a new treatment. The findings may not change practice without larger trials.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell chronic lymphocytic leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC LYMPHOCYTIC LEUKEMIA

Contacts and locations

Locations

Clinica Ematologica, Centro Trapianti e Terapie Cellulari "Carlo Melzi"

Udine, 33100, Italy
Clinica Luganese Moncucco

Lugano, 6903, Switzerland
Department of Haematology, Tor Vergata Hospital

Rome, 00133, Italy
Department of Medical and Surgical Sciences, section of Hematology

Modena, 41124, Italy
Dipartimento di Ematologia, Niguarda Cancer Center, Ospedale Niguarda

Milan, 20133, Italy
Division of Hematology, Department of Internal Medicine, Basel University Hospital

Basel, 4031, Switzerland
Divisione di Ematologia, Universita' del Piemonte Orientale

Novara, 28100, Italy
Ematologia, Ospedale di Circolo e Fondazione Macchi

Varese, 21100, Italy
Hematology, Luzern Kantonsspital

Lucerne, 6000, Switzerland
Institute of Hematology, Catholic University S. Cuore

Roma, 00168, Italy
Onco Ematologia Clinico Sperimentale, I.R.C.C.S. Centro di Riferimento Oncologico

Aviano, 33081, Italy
Oncology Institute of Southern Switzerland

Bellinzona, Switzerland, 6500, Switzerland
Ospedale San Raffaele

Milan, 20132, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.